Premium
Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions
Author(s) -
Sclar David A.,
Skaer Tracy L.,
Robison Linda M.,
Stowers Julie K.
Publication year - 1998
Publication title -
depression and anxiety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.634
H-Index - 129
eISSN - 1520-6394
pISSN - 1091-4269
DOI - 10.1002/(sici)1520-6394(1998)8:1+<121::aid-da18>3.0.co;2-x
Subject(s) - pharmacotherapy , antidepressant , depression (economics) , medicine , critical appraisal , psychiatry , intensive care medicine , tricyclic , tricyclic antidepressant , pharmacology , alternative medicine , economics , anxiety , pathology , macroeconomics
Abstract In the United States, an estimated $44 billion is expended annually for the treatment, morbidity, and mortality associated with depression. Domestic and international cost‐containment initiatives are mandating a demonstration of value for money defined in terms of a measurable health and/or financial outcome, and, in the case of medicines, attributable to a given expenditure for a given pharmacotherapeutic option. Recent pharmacotherapeutic advances in the treatment of depression have included the development of selective serotonin reuptake inhibitors (SSRIs), thereby providing an alternative to tricyclic antidepressants (TCAs). Herein, we review the pharmacoeconomic literature relative to antidepressant pharmacotherapy and identify issues for future inquiry. Depression and Anxiety, Volume 8, Supplement 1:121–127, 1998. © 1998 Wiley‐Liss, Inc.